美国2006-2015年子宫腺肌症的发病率、患病率与治疗:基于人群的研究
该回顾性队列研究纳入美国Kaiser Permanente Washington系统内16-60岁女性,计算2006-2015年子宫腺肌症的发病率、10年趋势和患病率。2015年患病率为0.8%,41-45岁最高(1.5%)。黑人女性发病率高于白人女性。82.0%的患者接受了子宫切除术。
要点
- 总体发病率为28.9/万女性年,10年间年龄标化发病率下降。
- 2015年患病率为0.8%,41-45岁女性患病率最高(1.5%)。
- 82.0%的患者行子宫切除术,37.6%使用慢性疼痛药物。
核心结论
- 子宫腺肌症对个体和医疗系统负担高,黑人女性发病率不成比例地高。
研究设计与样本
- 回顾性基于人群的队列研究,纳入2006-2015年美国Kaiser Permanente Washington系统内16-60岁女性,共333,693名女性贡献1,185,855女性年。
主要发现
- 发病率在41-45岁女性中最高(2008年69.1/10,000女性年),黑人女性最高44.6/10,000女性年(2011年)高于白人女性最高27.9/10,000女性年(2010年)。
- 2015年总体患病率为0.8%,41-45岁女性最高为1.5%。
- 90.8%有相关症状代码,18.0%合并子宫内膜异位症代码,47.6%合并子宫肌瘤代码。
- 82.0%行子宫切除术,近70%有提示子宫腺肌症的影像学检查,37.6%使用慢性疼痛药物。
关键数值与推荐
- ICD-9/ICD-10代码识别 incident 子宫腺肌症的阳性预测值为78.5%(95%CI 75.1%, 81.7%)。
临床怎么用
- 临床需关注子宫腺肌症的高疾病负担,尤其在黑人女性和41-45岁女性中。
- 现有长期药物治疗有限,子宫切除术仍是主要治疗方式,需开发管理计划并追踪结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adenomyosis symptoms are disabling. Population-based data on incidence and prevalence of adenomyosis are lacking that could guide future evidence-based treatments and clinical management. OBJECTIVE: To evaluate the incidence, 10-year secular trends, and prevalence of adenomyosis diagnoses and to describe symptoms and treatment patterns in a large U.S. cohort. STUDY DESIGN: We performed a retrospective population-based cohort study of women aged 16-60 years in 2006-2015, enrolled in Kaiser Permanente Washington, a mixed-model health insurance and care delivery system. Adenomyosis diagnoses identified by ICD codes from the International Classification of Diseases 9th and 10th editions and potential covariates were extracted from computerized databases. Women with prior hysterectomy, and for incidence estimates women with prior adenomyosis diagnoses, were excluded. Linear trends in incidence rates over the 10-year study period were evaluated using Poisson regression. Rates and trend tests were examined for all women adjusting for age using direct standardization to the 2015 study population, by age groups, and by race/ethnicity. Chart reviews were performed to validate diagnostic accuracy of ICD codes in identifying adenomyosis incidence. Symptoms and treatment patterns at diagnosis and in the following 5 years were assessed. RESULTS: A total of 333,693 women contributed 1,185,855 woman-years (2006-2015) for incidence calculations. Associated symptom-related codes (menorrhagia or abnormal uterine bleeding, dysmenorrhea or pelvic pain, dyspareunia, and infertility) were observed in 90.8%; 18.0% had co-occurrent endometriosis codes and 47.6% had co-occurrent uterine fibroid codes. The overall adenomyosis incidence was 1.03% or 28.9 per 10,000 woman-years, with a high of 30.6 in 2007 and a low of 24.4 in 2014. Overall age-adjusted estimated incidence rates declined during the 10-year study interval (linear trend P < .05). Incidence was highest for women aged 41-45 years (69.1 per 10,000 woman-years in 2008) and was higher for black (highest 44.6 per 10,000 woman-years in 2011) vs white women (highest 27.9 per 10,000 woman-years in 2010). Overall prevalence in 2015 was 0.8% and was highest among women aged 41-45 years (1.5%). Among the 624 potential adenomyosis cases identified by diagnostic codes in 2012-2015 and with sufficient information in the medical record to determine true case status, 490 were confirmed as incident cases, yielding a 78.5% (95% confidence interval, 75.1%, 81.7%) positive predictive value of adenomyosis ICD-9/ICD-10 codes for identifying an incident adenomyosis case. Health care burden was substantial: 82.0% of women had hysterectomies, nearly 70% had imaging studies suggestive of adenomyosis, and 37.6% used chronic pain medications. CONCLUSION: Adenomyosis burden to the individual and the health care system is high. Incidence rates are disproportionately high among black women. These findings are of concern, as currently available long-term medical therapies remain limited beyond hysterectomy. Our data and methodologies are novel and could serve as a foundation to guide clinicians and health care systems to develop clinical management plans and track outcomes for women with adenomyosis.
引用
- Yu O, Schulze-Rath R, Grafton J, et al. Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015. Am J Obstet Gynecol. 2020. PMID: 31954156. doi:10.1016/j.ajog.2020.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。